Posted by Michael Wonder on 10 Feb 2018
Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes
9 February 2018 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes.
Ozempic is a new once-weekly analogue of human glucagon-like peptide-1 indicated as monotherapy when metformin is considered inappropriate due to intolerance or is contraindicated, and as an addition to other medicinal products for the treatment of diabetes.
The marketing authorisation applies to all 28 European Union member states.
